Telomir Pharmaceuticals (NASDAQ: $TELO) just stitched together the kind of week that almost never happens at a sub-$50 million market cap. On April 24 the company closed the acquisition of TELI Pharmaceuticals, consolidating worldwide rights to its lead molecule and bringing up to $5 million in milestone-tied funding along with it. Six days later the company received FDA clearance on its IND for Telomir-Zn in advanced and metastatic triple-negative breast cancer (TNBC), openi